Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioStem TechnologiesBSEM -8.79%35 Equity-to-Asset is 0.57 as of Jun. 2026. GuruFocus rates BSEM with a GF Score™ of 35/100. The stock has 4 warning signs investors should review. Among 1,415 Biotechnology companies, BioStem Technologies ranks worse than 60.99% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. BioStem Technologies's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $27.62 Mil. BioStem Technologies's Total Assets for the quarter that ended in Jun. 2026 was $48.82 Mil.
Therefore, BioStem Technologies's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.57.
The historical rank and industry rank for BioStem Technologies's Equity-to-Asset or its related term are showing as below:
BSEM'
s Equity-to-Asset Range Over the Past 10 Years
Min: -2.23 Med: -0.82 Max: 0.8
Current: 0.57
During the past 13 years, the highest Equity to Asset Ratio of BioStem Technologies was 0.80. The lowest was -2.23. And the median was -0.82.
BSEM's Equity-to-Asset is ranked worse than 60.99% of 1415
companies
in the Biotechnology industry
Industry Median: 0.68
vs BSEM: 0.57
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
BioStem Technologies Equity-to-Asset Related Terms
BioStem Technologies Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for BioStem Technologies's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSEM vs RNTX, SPRO, ACRV: Equity-to-Asset Comparison
For the Biotechnology subindustry, BioStem Technologies's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioStem Technologies Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioStem Technologies's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where BioStem Technologies's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
BioStem Technologies's Equity to Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioStem Technologies (BSEM) has a Equity-to-Asset of 0.57 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on BioStem Technologies and its competitors. According to the industry distribution chart, BioStem Technologies ranks #863 out of 1415 companies in the Biotechnology industry, placing it in the top 61%.
Is BioStem Technologies' Equity-to-Asset too high?
BioStem Technologies' current Equity-to-Asset is 0.57. The Biotechnology industry median Equity-to-Asset is 0.68. BioStem Technologies' value of 0.57 is 16.2% below this industry median. Based on the distribution chart, BioStem Technologies ranks #863 out of 1415 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BioStem Technologies has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does BioStem Technologies' Equity-to-Asset compare to RNTX and SPRO?
According to the Biotechnology industry distribution chart, BioStem Technologies ranks #863 out of 1415 companies for Equity-to-Asset. This places BioStem Technologies in the lower half of its industry. The industry median Equity-to-Asset is 0.68. BioStem Technologies' value of 0.57 is 16.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,415 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioStem Technologies's current Equity-to-Asset of 0.57 is 16.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on BioStem Technologies and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioStem Technologies's current Equity-to-Asset is 0.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioStem Technologies stock overvalued right now?
BioStem Technologies (BSEM) has a current Equity-to-Asset of 0.57. The current Equity-to-Asset is 0.57 and 16.2% below the Biotechnology industry median of 0.68. BioStem Technologies' overall GF Score™ is 35/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For BioStem Technologies (BSEM), the current Equity-to-Asset is 0.57 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.
35GF Score
Get the complete analysis for BSEM
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSEM has been successfully added to your 
